Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Regeneron Pharmaceuticals Inc (NASDAQ:REGN)

455.17
Delayed Data
As of May 26
 -0.53 / -0.12%
Today’s Change
325.35
Today|||52-Week Range
464.40
+23.99%
Year-to-Date
Charting the Biotechs
May 26 / TheStreet.com - Paid Partner Content
Merck's HIV Drug Gets Positive CHMP Opinion for Higher Dose
May 22 / Zacks.com - Paid Partner Content
Regeneron Presents Positive Phase II Data on HoFH Candidate
May 25 / Zacks.com - Paid Partner Content
Compugen (CGEN) Worth a Look: Stock Adds 10.4% in Session
May 22 / Zacks.com - Paid Partner Content
The Zacks Analyst Blog Highlights: Regeneron, Amgen and Celgene
May 25 / Zacks.com - Paid Partner Content
Regeneron, Nuance Communications, Waste Management, Waste Connections and Republic Se...
May 17 / Zacks.com - Paid Partner Content
Boston Common Asset Management, LLC Buys Sociedad Quimica Y Minera De Chile SA, Albem...
May 25 / GuruFocus News - Paid Partner Content
Biotech Stock Roundup: Biogen Inks Deal to Boost Pipeline, Sangamo Soars on Pfizer De...
May 17 / Zacks.com - Paid Partner Content
Theravance/Mylan Presents Phase III Data on COPD Candidate
May 24 / Zacks.com - Paid Partner Content
Bull of the Day: Regeneron (REGN)
May 17 / Zacks.com - Paid Partner Content
Biotech Stock Roundup: FDA Nod for Regeneron RA Drug, Amgen Hit by Study Data
May 24 / Zacks.com - Paid Partner Content
TransEnterix (TRXC) Reports Wider-than-Expected Loss in Q1
May 15 / Zacks.com - Paid Partner Content
Merck Presents Phase II Data on Chronic Cough Candidate
May 23 / Zacks.com - Paid Partner Content
Bear of the Day: AMAG Pharmaceuticals (AMAG)
May 15 / Zacks.com - Paid Partner Content
Sanofi/Regeneron's Kevzara Gets FDA Approval for Arthritis
May 23 / Zacks.com - Paid Partner Content